



# Fineotex Chemical Ltd.

## Q3FY25



## Fineotex Chemical Ltd.

**Tough macro leads to weak quarter, awaiting positive triggers**

CMP* <b>INR 254</b>	Target <b>INR 366</b>	Potential Upside <b>43.9%</b>	Market Cap (INR Mn) <b>INR 29,245</b>	Recommendation <b>BUY</b>	Sector <b>Specialty Chemicals</b>
------------------------	--------------------------	----------------------------------	--	------------------------------	--------------------------------------

- Fineotex Chemical Ltd(FCL) posted muted sales and volume growth for Q3FY25; primarily driven lower by a challenging demand environment in FMCG, textiles segment grew by 20% in volumes, exports also haven't been able to keep up pace due to issues in Bangladesh.
- On a 9month basis revenues remained stable coming in at INR 4,135 Mn (-0.6% YoY), EBITDA margin was also flat at 26% declining by 26 bps.
- FCL has launched 30 new products in textile chemicals. FCL has also announced the launch of their water-based mosquito repellent "AquaStrike", we believe water treatment and Oil & Gas verticals will drive growth going forward.
- We introduce FY27 estimates, with a 3yr revenue CAGR of 16% and EBITDA margins of 28%. Considering upcoming positive triggers for the company: a) buoyancy in the textile markets b) upcoming inorganic expansions b) new sustainable product launches, we value the company at 20x FY27E EPS of INR 16.6 to arrive at a target price of INR 366 implying an upside of 43.9%.**

### MARKET DATA


Shares outs (Mn)	115
Equity Cap (INR Mn)	4,536
Mkt Cap (INR Mn)	29,245
52 Wk H/L (INR)	459 / 263
Volume Avg (3m K)	338
Face Value (INR)	2.0
Bloomberg Code	FTXC:IN

### KEY FINANCIALS

Particulars (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Sales	5,170	5,690	5,895	7,206	8,871
EBITDA	1,126	1,484	1,552	1,915	2,458
PAT	896	1,210	1,306	1,559	2,023
EPS	7.9	10.8	11.2	12.8	16.6
EBITDA Margin (%)	22%	26%	26%	27%	28%
PAT Margin (%)	17%	21%	22%	22%	23%

Source: Company, Deven Choksey Research

### SHARE PRICE PERFORMANCE



### MARKET INFO

SENSEX	75,967
NIFTY	22,945

### Muted Growth during the quarter affected by order postponements and geopolitical issues

Revenue degrew by 9% on a YoY for Q3FY25 coming in at INR 1,259 Mn. The drop in sales was precipitated by a) order postponements b) contraction in Cleaning & Hygiene Segment and c) lower realizations across products. Textile segment posted healthy with addition of 30 new customers, volumes rising by 20% and revenues by 12%. The order postponements was most likely due to issues with supply chains being affected in Bangladesh and will likely resolve over the next few quarters. Share of exports in the overall revenue has dropped to 19% from 24% a year ago.

### New Product Launch – AquaStrike Premium marks entry into Water Chemicals Segment

FCL has launched a new product called AquaStrike, based on Azadirachtin. Azadirachtin is a compound also found in neem and is considered a very effective insecticide. FCL plans to market this product for mosquito repellent properties and water soluble and sustainable properties. The TAM for a product is very large, while existing practices involve local governments spraying smoke-based chemicals. With this new sustainable product, it can open new doors for the water segment of the company. Further, with surfactants and

### Updates on Inorganic Expansion & New Manufacturing Facility Progress

FCL has raised 3,425 Mn in placements of equity shares and warrants which will be received over the next 9-10 months. Management wishes to deploy these funds in an EPS accretive manner via inorganic acquisition. We remain hopeful of management being able to deploy this cash soon, if undeployed the cash would drag down ROE/ROCE multiples.

### Dividend of INR 0.40/share approved by Board

The board has approved a dividend of INR 0.40/share totalling to INR 45.8 Mn as Interim Dividend for FY25.

### SHARE HOLDING PATTERN (%)

Particulars	Dec-24	Sep-24	Jun-24
Promoters	63.0	63.0	64.5
FIIIs	3.3	3.2	0.9
DIIIs	3.6	3.6	3.7
Others	30.1	30.2	30.9
Total	100	100	100

\*Based on today's closing

16%

Revenue CAGR between  
FY24 and FY26E

19%

PAT CAGR between FY24  
and FY26E

**Fineotex Chemical Ltd.****Key Concall Highlights:**

- 1. Strong Growth in expected in new segments:** Fineotex is witnessing robust growth in oil & gas and water treatment segments, with a strong order pipeline expanding geographically. Diversification into high-demand industries like specialty chemicals for industrial applications enhances long-term stability.
- 2. Sustainability and Innovation at the Core:** The company has launched 30 new products this quarter, focusing on eco-friendly and high-performance solutions. A key innovation, AquaStrike Premium, is a biotechnology-based, eco-friendly mosquito control solution, presenting a strong market opportunity.
- 3. Expanding Production Capacity:** A new manufacturing facility is expected to be operational by Q2 FY26, increasing production efficiency and supporting growing demand. The company is implementing renewable energy solutions, including a 100-kilowatt solar plant at Ambarnath, and optimizing processes for zero discharge of hazardous chemicals.
- 4. Financial Performance & Profitability:** Revenue has grown at a CAGR of 30.5% since 2020, while profits have increased at a CAGR of 70.5% over the same period. EBITDA margins remained healthy at 27.2%, indicating strong operational efficiency.
- 5. Export Slowdown & Future Rebound** Management expects a revival in exports as the political situation stabilizes and Bangladesh's financial system improves.
- 6. Textile Segment Showing Resilience:** Textile business grew 20% in volume and 12% in revenue this quarter, compensating for muted demand in FMCG. India is gaining traction as a global textile hub, further boosted by strong participation in international textile exhibitions.
- 7. Inorganic Growth & Acquisition Strategy:** The company has earmarked INR 300 crores for acquisitions, with a focus on EPS-accretive deals. Ongoing M&A discussions are progressing cautiously, ensuring synergy and disciplined capital allocation before finalizing any acquisitions.
- 8. Geopolitical Tailwinds in Oil & Gas:** The company is benefiting from the shift away from China in oil & gas specialty chemicals. Fineotex has secured major orders from Eastern Europe, Middle East, and Africa and is actively pursuing strategic partnerships with industry giants.
- 9. FMCG Sector Recovery Expected:** While FMCG demand was muted, management anticipates a rebound due to favorable taxation policies and rural demand recovery. The upcoming summer season is expected to boost demand for hygiene and cleaning products, further aiding growth.
- 10. Credit Ratings:** ICRA upgraded Fineotex's credit rating outlook to positive, reflecting financial strength and robust expansion plans. Investors can expect sustained long-term growth, driven by diversification, strong R&D, sustainability, and disciplined financial management.

**Valuation and view:**

As the macro situation continues to be unstable, FCL has managed to hold its own. With 9MFY25 revenues remaining stable, while EBITDA margins continue to hover around 26%. We believe with the upcoming new product launches, further pickup in textiles end use sector, inorganic expansion opportunity there's scope for growth and fundamentally the company remains strong.

We introduce FY27E estimates assuming a revenue growth of 23% and EBITDA margin With the upcoming triggers expected from possibility of inorganic expansion, growth in textile segment, new sustainable products we roll forward our valuation to FY27E with a Price to earning of 22x on an EPS INR 16.6 to arrive at a target price of INR 366/share. Consequently , we maintain our "BUY" rating on the stock with an upside of 43.9%.

## Fineotex Chemical Ltd.


### Result Snapshot

Particulars (Mn)	Q3FY25	Q2FY25	Q3FY24	QoQ	YoY	9MFY25	9MFY24	YoY
<b>Net Sales</b>	<b>1,259</b>	<b>1,457</b>	<b>1,385</b>	<b>-13.6%</b>	<b>-9.1%</b>	<b>4,135</b>	<b>4,160</b>	<b>-0.6%</b>
<b>Raw Materials</b>	793	830	789			2,553	2,444	
Cost of materials	20	50	31			73	109	
Purchase of traded goods	(72)	20	(10)			(114)	(17)	
(Increase)/Decrease in Stock	<b>740</b>	<b>900</b>	<b>810</b>		<b>-8.6%</b>	<b>2,512</b>	<b>2,536</b>	
<b>Gross Profit</b>	<b>519</b>	<b>557</b>	<b>574</b>	<b>-6.9%</b>	<b>-9.7%</b>	<b>1,623</b>	<b>1,624</b>	<b>0.0%</b>
<b>Gross Margin (%)</b>	<b>41.19%</b>	<b>38.22%</b>	<b>41.47%</b>	<b>297 bps</b>	<b>-28 bps</b>	<b>39.25%</b>	<b>39.03%</b>	<b>22 bps</b>
Employees cost	61	61	55	-0.9%	11.1%	178	156	13.7%
Other Expenses	115	132	116	-12.7%	-0.8%	386	366	5.4%
<b>EBITDA</b>	<b>343</b>	<b>364</b>	<b>404</b>	<b>-5.8%</b>	<b>-15.0%</b>	<b>1,059</b>	<b>1,101</b>	<b>-3.8%</b>
<b>EBITDA Margin (%)</b>	<b>27%</b>	<b>25%</b>	<b>29%</b>	<b>226 bps</b>	<b>-191 bps</b>	<b>26%</b>	<b>26%</b>	<b>-85 bps</b>
Depreciation	26	24	14	9.2%	81.0%	72	42	72.9%
<b>EBIT</b>	<b>317</b>	<b>340</b>	<b>389</b>	<b>-6.8%</b>	<b>-18.5%</b>	<b>987</b>	<b>1,059</b>	<b>-6.8%</b>
Other income	50	69	49	-27.7%	1.0%	168	124	35.3%
Interest	2	2	3	-4.9%	-30.6%	7	7	-10.8%
<b>EBT</b>	<b>365</b>	<b>407</b>	<b>436</b>	<b>-10.4%</b>	<b>-16.2%</b>	<b>1,148</b>	<b>1,176</b>	<b>-2.3%</b>
Tax	87	86	106	0.2%	-18.7%	257	270	-4.7%
<b>PAT</b>	<b>278</b>	<b>321</b>	<b>329</b>	<b>-13.2%</b>	<b>-15.5%</b>	<b>891</b>	<b>905</b>	<b>-1.6%</b>
<b>Net Margin (%)</b>	<b>22.10%</b>	<b>22.01%</b>	<b>23.78%</b>	<b>10 bps</b>	<b>-168 bps</b>	<b>21.54%</b>	<b>21.77%</b>	<b>-23 bps</b>
Non-controlling interests	2	2	3	(8.2%)	(22.3%)	8	8	(1.1%)
<b>PAT (attributable to shareholders)</b>	<b>276</b>	<b>319</b>	<b>327</b>	<b>-13.24%</b>	<b>-15.42%</b>	<b>882</b>	<b>897</b>	<b>-1.63%</b>
<b># Shares</b>	<b>116</b>	<b>116</b>	<b>116</b>			<b>116</b>	<b>116</b>	
<b>Adj. EPS</b>	<b>2.43</b>	<b>2.75</b>	<b>2.82</b>	<b>-11.58%</b>	<b>-13.79%</b>	<b>7.61</b>	<b>7.74</b>	<b>-1.63%</b>

Source: Company, DevenChoksey Research


## Fineotex Chemical Ltd.

### Growth moderates due to macro challenges



Source: Company, DevenChoksey Research

### Margins remain steady



Source: Company, DevenChoksey Research

## Fineotex Chemical Ltd.

### KEY FINANCIALS

#### Exhibit 1: Profit & Loss Statement

Income Statement (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
<b>Revenue from operation</b>	<b>5,170</b>	<b>5,690</b>	<b>5,895</b>	<b>7,206</b>	<b>8,871</b>
Cost of goods sold (COGS)	3,392	3,488	3,606	4,426	5,506
Employee benefits expense	184	212	190	196	197
Other expenses	468	506	547	669	710
<b>Total Expenses</b>	<b>4,044</b>	<b>4,206</b>	<b>4,343</b>	<b>5,291</b>	<b>6,413</b>
<b>EBITDA</b>	<b>1,126</b>	<b>1,484</b>	<b>1,552</b>	<b>1,915</b>	<b>2,458</b>
Depreciation and amortization expense	43	60	63	73	73
EBIT	1,083	1,424	1,489	1,841	2,385
Other income	73	165	215	279	363
Finance costs	8	13	14	14	14
<b>Profit before tax</b>	<b>1,148</b>	<b>1,576</b>	<b>1,690</b>	<b>2,107</b>	<b>2,734</b>
Exceptional items - income / expense	0	0	0	0	0
<b>Profit / loss before tax</b>	<b>1,148</b>	<b>1,576</b>	<b>1,690</b>	<b>2,107</b>	<b>2,734</b>
Current tax	242	348	0	0	0
<b>Total Tax expense</b>	<b>252</b>	<b>365</b>	<b>384</b>	<b>548</b>	<b>711</b>
<b>Profit after tax</b>	<b>896</b>	<b>1,210</b>	<b>1,306</b>	<b>1,559</b>	<b>2,023</b>

Source: Company, Deven Choksey Research

#### Exhibit 2: Cash Flow Statement

Cash Flow Statement (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Net Cash Generated From Operations	1,073	974	1,408	1,409	1,803
Net Cash Flow from/(used in) Investing Activities	-1,018	-469	-3,227	-3,175	-20
Net Cash Flow from Financing Activities	-64	-239	1,912	1,486	-14
Effect of exchange differences	24	-6	0	0	0
Net Inc/Dec in cash equivalents	14	260	93	-280	1,770
Opening Balance	289	303	563	657	376

Source: Company, Deven Choksey Research

#### Exhibit 3: Ratio Analysis

Key Ratios	FY23	FY24	FY25E	FY26E	FY27E
EBITDA Margin (%)	21.8%	26.1%	26.3%	26.6%	27.7%
Tax rate (%)	22.0%	23.2%	22.7%	26.0%	26.0%
Net Profit Margin (%)	17.3%	21.3%	22.2%	21.6%	22.8%
RoE (%)	28.7%	29.9%	21.2%	16.8%	17.1%
EPS (INR)	8.0	10.8	11.3	12.8	16.6
CFO/EBITDA	95.3%	65.6%	90.7%	73.6%	73.4%

Source: Company, DevenChoksey Research

#### Exhibit 4: Balance Sheet

Balance sheet (INR Mn)	FY23	FY24	FY25E	FY26E	FY27E
Property, plant & equipment	888	1,310	1,247	1,409	1,336
Capital work in progress	4	0	235	0	0
Investment property	39	39	39	39	39
Goodwill on consolidation	61	61	61	61	61
Investments	893	1,080	4,051	7,207	7,207
Others	24	16	16	16	16
Non - current tax assets	33	76	76	76	76
Other non - current assets	45	41	41	41	41
<b>Total non - current assets</b>	<b>1,988</b>	<b>2,623</b>	<b>5,767</b>	<b>8,849</b>	<b>8,776</b>
Inventories	473	501	503	617	768
Investments	0	388	390	225	2,151
Trade receivables	1,014	1,388	1,156	1,413	1,740
Cash and cash equivalents	376	227	319	368	420
Bank balances	220	172	172	172	172
Other financial asset	7	21	21	21	21
Other current assets	77	90	90	90	90
Asset classified as held for sale	72	72	72	72	72
<b>Total current assets</b>	<b>2,239</b>	<b>2,858</b>	<b>2,722</b>	<b>2,977</b>	<b>5,432</b>
<b>Total assets</b>	<b>4,227</b>	<b>5,482</b>	<b>8,489</b>	<b>11,826</b>	<b>14,208</b>

#### Equity and Liabilities

Equity share capital	221	222	232	240	240
Other equity	3,265	4,249	7,471	10,521	12,544
Minority interest	70	65	65	65	65
<b>Total equity</b>	<b>3,557</b>	<b>4,536</b>	<b>7,767</b>	<b>10,826</b>	<b>12,849</b>
Other financial liabilities	10	10	10	10	10
Provisions	0	3	3	3	3
Deferred tax liabilities (net)	21	39	39	39	39
<b>Total non - current liabilities</b>	<b>32</b>	<b>52</b>	<b>52</b>	<b>52</b>	<b>52</b>
Borrowings (overdraft)	73	52	52	52	52
Trade payables	474	728	503	618	769
Other financial liabilities	2	6	6	6	6
Other current liabilities	87	103	103	103	103
Provisions	4	4	4	4	4
Current tax liabilities (net)	0	0	0	0	0
<b>Total current liabilities</b>	<b>638</b>	<b>894</b>	<b>670</b>	<b>784</b>	<b>935</b>
<b>Total liabilities</b>	<b>670</b>	<b>946</b>	<b>721</b>	<b>836</b>	<b>987</b>
<b>Total equity and liabilities</b>	<b>4,227</b>	<b>5,482</b>	<b>8,489</b>	<b>11,662</b>	<b>13,836</b>



## Fineotex Chemical Ltd.

Fineotex Chemicals Limited			
Date	CMP (INR)	TP (INR)	Recommendation
18-Feb-25	254	366	BUY
15-Nov-24	348	476	BUY
12-Aug-24	367	529	BUY
31-May-24	355	573	BUY
20-Feb-24	436	571	BUY

Rating Legend (Expected over a 12-month period)	
Our Rating	Upside
Buy	More than 15%
Accumulate	5% – 15%
Hold	0 – 5%
Reduce	-5% – 0
Sell	Less than – 5%

### ANALYST CERTIFICATION:

I, **Karan Kamdar** (CA), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

### Terms & Conditions and other disclosures:

DRChoksey FinServ Private Limited (hereinafter referred to as DCFPL) is a registered member of SEBI as a Research Entity vide Registration No. INH000011246 under SEBI (Research Analyst) Regulations, 2014, Portfolio Managers Entity vide Registration No. INP000007906 under SEBI (PORTFOLIO MANAGERS) Regulations, 2020 & Investment Adviser Entity vide Registration No. INA000017903 under SEBI (INVESTMENT ADVISERS) REGULATIONS, 2013.

The information and opinions in this report have been prepared by DCFPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of DCFPL. While we would endeavor to update the information herein on a reasonable basis, DCFPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent DCFPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or DCFPL policies, in circumstances where DCFPL might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. DCFPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. DCFPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

We submit that no material disciplinary action has been taken on DCFPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

DCFPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

It is confirmed that, I, **Karan Kamdar** Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

DCFPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

DCFPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

DCFPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. DCFPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither DCFPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

It is confirmed that, **Karan Kamdar**, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

DCFPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject DCFPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

The securities quoted are for illustration only and are not recommendatory

Please send your feedback to [research.retail@devenchoksey.com](mailto:research.retail@devenchoksey.com)

DRChoksey FinServ Private Limited

CIN Number -U67100MH2020PTC352816

**Registered Office and Corporate Office:**

5th Floor Abhishek Building, Behind Monginis Cake Factory, Off New Link Road, Andheri West, Mumbai-400058